BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/15/2019 10:34:38 AM | Browse: 952 | Download: 1657
 |
Received |
|
2019-01-30 02:52 |
|
Peer-Review Started |
|
2019-01-30 22:08 |
|
To Make the First Decision |
|
2019-03-18 06:32 |
|
Return for Revision |
|
2019-03-22 01:35 |
|
Revised |
|
2019-03-28 08:36 |
|
Second Decision |
|
2019-04-04 10:33 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-04-08 21:36 |
|
Articles in Press |
|
2019-04-08 21:36 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-05-14 02:21 |
|
Publish the Manuscript Online |
|
2019-05-15 10:34 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Observational Study |
| Article Title |
ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hiroaki Takaya, Tadashi Namisaki, Naotaka Shimozato, Kosuke Kaji, Mitsuteru Kitade, Kei Moriya, Shinya Sato, Hideto Kawaratani, Takemi Akahane, Masanori Matsumoto and Hitoshi Yoshiji |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hiroaki Takaya, MD, PhD, Assistant Professor, Doctor, Doctor, Third Department of Internal Medicine, Nara Medical University, 840 Shijo-cho, Kashihara 6348522, Japan. htky@naramed-u.ac.jp |
| Key Words |
ADAMTS13; Von Willebrand factor; Biomarkers; Hepatocellular carcinoma; Sorafenib |
| Core Tip |
There is an urgent clinical need to prediction of sorafenib response and prognosis in patients with hepatocellular carcinoma (HCC) receiving sorafenib treatment due to the potentially serious side effects of sorafenib in these patients. Multivariate analysis showed that the von Willebrand factor (VWF) antigen (VWF:Ag)/a disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) activity (ADAMTS13:AC) ratio was the only predictive factor for sorafenib response and ADAMTS13:AC was the only prognostic factor in patients with HCC receiving sorafenib treatment. The VWF:Ag/ADAMTS13:AC ratio and ADAMTS13:AC are potentially useful biomarkers for sorafenib response and prognosis, respectively, in patients with HCC receiving sorafenib treatment. |
| Publish Date |
2019-05-15 10:34 |
| Citation |
Takaya H, Namisaki T, Shimozato N, Kaji K, Kitade M, Moriya K, Sato S, Kawaratani H, Akahane T, Matsumoto M, Yoshiji H. ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma. World J Gastrointest Oncol 2019; 11(5): 424-435 |
| URL |
https://www.wjgnet.com/1948-5204/full/v11/i5/424.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v11.i5.424 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
